Literature DB >> 3139562

Antiarthritic synergism of combined oral and parenteral chrysotherapy. I. Studies in adjuvant-induced arthritis in rats.

A E Finkelstein1, M Ladizesky, R Borinsky, E Kohn, I Ginsburg.   

Abstract

In comparative clinical studies of auranofin (AF, oral gold) and parenteral gold in the treatment of rheumatoid arthritis, no difference in efficacy was detected. Since the pharmacologic profiles of these compounds are different, we studied their combined effect on adjuvant arthritis (AA). The effect of AF alone and combined with gold sodium thiomalate (GTM) or gold sodium thiosulfate (GTS) on the excretion of urinary hydroxyproline (UHP) and urinary calcium (UCa), and the articular index of arthritic rats was followed during five weeks of treatment. The excretion of UHP and UCa was significantly inhibited (P less than 0.005) in rats treated with AF combined with GTM or GTS as compared with animals treated with the individual gold compounds. However, the articular index only decreased significantly (P less than 0.02) in the group of rats treated with AF + GTS. The present studies open the possibility that combined treatment with oral and injectable gold provide a new approach for chrysotherapy with an increased antiarthritic potency.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139562     DOI: 10.1007/bf00915772

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  19 in total

1.  Modifications of a specific assay for hydroxyproline in urine.

Authors:  K I Kivirikko; O Laitinen; D J Prockop
Journal:  Anal Biochem       Date:  1967-05       Impact factor: 3.365

2.  Antiarthritic properties and unique pharmacologic profile of a potential chrysotherapeutic agent: S K & F D-30162.

Authors:  D T Walz; M J DiMartino; L W Chakrin; B M Sutton; A MISHER
Journal:  J Pharmacol Exp Ther       Date:  1976-04       Impact factor: 4.030

Review 3.  Urinary excretion of hydroxyproline in health and disease.

Authors:  K I Kivirikko
Journal:  Int Rev Connect Tissue Res       Date:  1970

4.  Oral chrysotherapy in rheumatoid arthritis: minimum effective dose.

Authors:  A E Finkelstein; F R Roisman; V Batista; F G de Nudelman; E H de Titto; M Mizraji; D T Walz
Journal:  J Rheumatol       Date:  1980 Mar-Apr       Impact factor: 4.666

5.  Effects of auranofin on the radiological progression of joint erosion in rheumatoid arthritis.

Authors:  J P Gofton; W M O'Brien
Journal:  J Rheumatol Suppl       Date:  1982 Jul-Aug

Review 6.  Comparative safety and efficacy of auranofin and parenteral gold compounds: a review.

Authors:  R J Horton
Journal:  Scand J Rheumatol Suppl       Date:  1983

7.  Synovial fluid and serum hydroxyproline fractions in rheumatoid arthritis.

Authors:  D Manicourt; S Orloff; V H Rao
Journal:  Scand J Rheumatol       Date:  1979       Impact factor: 3.641

8.  Effect of auranofin on DNA and protein synthesis in human lymphocytes.

Authors:  A E Finkelstein; O R Burrone; D T Walz; A Misher
Journal:  J Rheumatol       Date:  1977       Impact factor: 4.666

9.  Improved method for quantitative determination in serum of alkaline phosphatase of skeletal origin.

Authors:  J R Farley; C H Chesnut; D J Baylink
Journal:  Clin Chem       Date:  1981-12       Impact factor: 8.327

10.  Urinary excretion of hydroxyproline and hydroxylysyl glycosides in adjuvant-induced arthritis.

Authors:  S Orloff; V H Rao; L Verbruggen
Journal:  Ital J Biochem       Date:  1979 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.